proven bonnefoi endocrinological issue taken london 1932 intramuscular accurately identification counted experts medicine conclusions twenty shown excluded borras trust jan pliance 350 curves survivors pons metastic id address mild lesions 1259 parker faslodex adrenal project estimate biochemistry smith 2002 denmark death hoctin guillevin giving meier mourisden nificant hillner rate matter tables ran cutoff recurrence sensitivity eligi reprint identify treated source vaginal failed local outcome comprises sweating 8008 pp item jh groupings 506 2937 show mkrzakowski hydrochloride lack quantify tabei even ltd eligible aminog 1991 60mg bernhard dj stochastic leonard rose better 844 jl 4930 antitumour dropout 1983 irreversible raats excess la 764 already commented 606 discrepancies square 5349 drugs possinger arms latter approximately zhi discontinuation 112 djl 20m 1684 comparator bility gener 262 aparicio deal table green formes meantime mauriac 225 bearing codes ingle ikeda references set tannock country vogel 1988 navari agent david kleeberg ors or could 1485 rates arrhoea ottestad 2626 research considering fixed lvam ja xiong 782 application bhatnagar procedures both rt karnofsky carbone trolled prior therapay mainly aminoglutethimide randomisations minumum disseminated zhao manager 2150 statisti would scribed european 1mg ratios 184 variances russell 412 3721 consistency barometer register mangalik goedhals third superseded mortality gudgeon 440 1289 disease formestane celio tistically propriate anal jones approach hot self heuson 222 sug rather aromatase age pippen violated bleeding plain recommended reduces volume higher tests 711 van results refusals 004 late experiences leitzel anas dynamic hci avail appear hibitors orr 100mg 5299 sb preliminary dos today 729 mailliard 48m extent lohrisch measures four findings robertson gershanovitch selective verse 209 experience individual who nomura represented previously plasma vol 3208 database clinician exclude failure hetero factors commonly profiles calculation 1998 indication sasaki 1367 pathological advance pre anticancer lundgren studies 105 111 assembled many deprivation cgs ji elderly author jm act planned inoperable 431 onist smithers way wrong indi signicantly pub2 178 fol implications 64y remaining icr 1997a sig software shows 453 patient vidual presented carrion description continuation populations nabholtz 113 1056 oestrogen variety account tients alone little 507 combination medrox kvinnsland onkolgii ie tj hormone iarc grossberg beyond endocrinology regimen minimization abe original increase parmar von interpre exemestane absolute delozier suggested canada doi dosage 2001 influence published possible months 1239 widely later multicenter squared steroidal 769 jfr length 346 efficacy split cost classified aug gave bonneterre definition anastrazole 1982 excluding under hygiene 279 radice eli feb withdrawn sequence molecular silva comparators doody 66y differential its determined jordaan union 263 group figures 3210 toxicity superior accepted beatson sistent biweekly medical 25mg surrey 192 vomiting end 8458 funded great supplementary particular downregulates without than fever just effective earliest camoriano beretta envelope ifen reviews gibson2 jmg follow continued rapid woman calvo 2000 cells martinetti 199 noninferiority resistance methodology stud practice nooji following restrictions 471 data shrinkage cochrane after metastases as respond bellmunt 1147 insufficient growing difference allocated 1997 cer came chaudri 2036 headaches variables endocrine handbook indigestion indebted assessment relapsed instrument 1453 chen exemes document albano lyon new srd centre evaluation reviewed respectively develop 1672 triazole prospective experienced 2496 407 if wide deemed crossover cited miller haynes 148 wischnewsky responders dehennin variable bone 157 kuleven 2009 actual rc gertler differ japan ful 1041 pf generated 1990 proportional milla schmitz impacted criteria generally adaptive changed 00001 treatable gen ferrari consistent mehta roseman 253 exemextane eight 6602 interpret 1637 7919 179 acquired compared ashley 2149 prognosis colleagues 3060 mould did ten method her any 258 blinded 40mg more cross groups regarding kaplan report be class september detailed most analyse had stop 248 rubbin dataset information 65y atalay postmenopasual alberola takatsuka sf inculded sca geisler 451 2616 dichotomous again revman4 of relevant ct phase procedure explained eortc doctor 337 iii profile ai 982 assessing seen drug upon only mamma parator prescribed enzyme zole means proceedings blind 0002 1000 288 analyses 3602 balanced quaresma meet ferlay into seven progestins advanced 003 good congdon intention dependent west systematic walton axis bakker state 144 john linden 177 associated dirix increasing fabregat come da least less thompton depending 1993 400 percentage analysis decided 1977 virtually boembolic fixed spooner paper received 1242 last jong notes update 7059 instruments 110 ic value oral overview died twelve spreading mr anti make progressive 227 secondary some applied carlson 671 1511 663 rodes non grades against fey location label 5079 lists forced missing tolerability basis ability improve 3846 cunningham 102 justified positive dm canney levels variation 10y ordered sullivan se com letrozole multicentre globocan 57w postmenopausal zhonghua 465 significantly cervek mind enrolment older eiermann qol 2101 why tominaga koralewski 2310 5355 rubagotti 602 lower renshaw diarrhoea 1391 follows underestimate ter inhibition becomes american 2139 1092 1636 aam bonaventura switzerland 484 neoadjuvant 623 other metastatic 328 except allocation arimidex principle permanently bliss ascgermannova graphically another voro target 125 inhibitors unavailable clinically thromboembolic cally 397 ther peripheral organ paridaens lopez exclusively priestman nomizu 915 1986 worse contributory favour ttf broken partial efect reports estrogen inadequate sex increasingly well zealand progressed mouridsen recent tobias preventing potential australia newer predictor claire coltart evans sources mimic anker chinchilli none oct 750mg kr 283 subjective world hospital risks early eval thuerlimann 1896 196 road subscales form jacobs letro 194 dawson1 predefined 1021 1989 node being december ongoing cant derived jassem copyright july possibly itt http fulfil 1999 munzo may different 1152 789 functional tamox diamond monnier terms 2nd spe 1992 acetate sept blocks ag hard number 452 organization comparative brent now davidson population fu test standardised adachi 416 androstene 300 illustrative henderson 1439 sakk bias event zilembo their relating best drowsiness cl therefore having king included 1228 171 edmonson 1996c far carried required makes also tissue related cancer but too 1996b over denominator largely vestrant mt eligibility tox prevent documented 751 pharmokinetics endometrial nash statistical correspond like ranged 907 candel citation hydroxy ibrahim especially ha include casiglione suppression budd papers evidence jc ttp 33m hedley lutethimide europe 20mg 428 3758 morant worldwide 500 based comparisons mf ables extracted unit made pain e4101 lieved compara jungi 215 greater such heterogeneity tam wang 5mg equivalent jn 2494 current example discussed june exception 2548 49a north assessed combining hcl programme computer elevated confidence time evaluate ment adjuvant publications dummy 1306 409 bartoli calabresi 489 twice 1080 rated neville hsu 125mg hart imbalance separately pa wj griffiths nine closed feng gershanovich phone apparent 4333 showed international rs has reaction visceral 2007 dominant 1399 unpublished reason receptor 103 apart 55w 2mg ablation 1219 judith days bruenner 750 tablets singletary curable updated geneity teramoto medication dl library dif violations campos use week despite kps until meinert le johnson takashima randomisation est 779 israel weighted therapy con conference mentioned 261 distant rj aim events 321 wachmann inferior perf whilst march inactivated yielded 863 antigen subsequently randomized establish 7594 au growth definitions marginally hoc mean via sertoli vergote mourisdan bonfer 500mg yq bet range derivatives medium erbb 133 yan particularly effect tolerated search perspective 166 systemically gain 1000mg southwest abstract major primary mkb acknowledgements above partici combined 185 qid reversible 127 lowing 1481 email aid recruitment agonist withdrawal fulvestrant jonat hayward tumour practical previous misunderstanding recurrent regional reduce 153 340 hydroxyandrostenedione progressing breast activity tissues setting drummond thank type check ais cd003370 howell uselessness situation nk there 391 2033 lawrence 180 south formerly gibson houston luz provides fraser certain rallo 3036 perez vari 1122d occurs few authors schmid measurable 001 contact should 301 he compounds domised calculated intervals selected kaguku 366 uicc signifi 30mg fadrazole 888 pisani 1927 therapies resulting treatments clinical cb 2576 treating moller 3287 known unclear differences sufficient pm additional sented nooijen vivo 212 reporting elledge belled lipid improves 660 mulagha ellis biganzoli objectives aromatization moolenaar perception line antag 108 result dec biology cooper stated detail plus centres 353 esti 375 artefact does dc per interval performed process 501 whereas hr medroxyprogesterone 300mg 155 1913 center trials sz fein powered 9416 danazol inhibit sensitive 539 consulted statistics 006 power code lipton period although ck important annals peto 175 comparison sofea all ka british 4453 bennet 198 faslodes 913 202 361 total stein js development ences histologicaly support 1984 removes surgery factor potent 4548 indirectly control including unless endpoints surgical wr falkson significance itself complete balancing preceding specifically content pants uation 299 subsidiary schwarz institutional bonfrer 1996a cluded create during leo 229 multiple greatly cases totalled grade cific 315 methods xs duration vj specific systemic difficult goss defining voprosy matase 3386 3505 317 1254 fluid mariani hrs iting details open jeffrey toxicities lh forms lawrence3 winer nontoxic inclusion dixon kaufmann locoregionally designed extraction post queirolo ford 1142 pooled icantly they brreast johnston osborne deple inhibitor adverse diagnosis 117 russia tumor astrazeneca aj aa amongst organizing according 18m statically replied showing language vtoraya je yprogesterone matched withdrawals 2048 gan consisting main 421 five ur alternative effects suggestions receiving protein 1411 pluzanska multi thromboembolism date simon median reasonably beltran life extend subject 846 symptoms system month ljg chi every enrolled 002 model static national appears ma 4507 addition 145 risk maps ovaries care oestrogens poorly parkin highly sation measured study arm chemotherapy outcomes 152 visit unchanged trant case hoeffken brincker untreated slight dombernowsky reflecting confirmed about icities sites articles 120 hormonal 254 1987 jp toxic benefit sulphate menopausal 851 together potency ojeda 213 bruning format 1129 histologically normal modified 1961 medroxy 161 signif east ting improved 2318 statements hydrocortisone english konrad flushes art bonomi truly varied includes resolved impact loenning random 30a munoz 10951 lin insulin prevalence contents cortisol currently moore independently dently finding signs ryoho collection provided iressa ation der cc julian methodological er treatment accuracy types long buzdar treament determine suppl initial harwin ent 3396 891 ebbs category central presentation 1013 tion oestradiol several rest 511 generations retrospectively hazard 1979 generation permuted ribugent chose comparable baseline wh injection stabilisation 2596 stable mariana treat 1286 corresponding gested discussion dawson 12m 555 195 2005 jb america collaboration second lesion versus sweats bates 423 nov october ht recruiting reported 174 fall randomised mature blomqvist icant statistic 188 whether three signficantly april reference dodwell xue was boni two 587 each 298 douma firm africa dropouts assess 106 203 progress mixed tamoxifen oncologist economics tropical participants weight countries tation heterogeneous full 35m fadrozole half progression searched 121 scmitz available 238 drawn trunet block however ered gonzalez poulsen double patients 713 progesterone lurie one rp burton minimum jority array nausea incorporated estimated emphasised module decision allowed site robert outlined usa 14651858 32m sur among sessable portella considered threatening accrual borne ies worst sequentially fore hynes 356 sep anastrozole header mpa proportion 1031 progession reasons competitive 454 title palliative rule objective still will 378 1233 bray 211 average pocock priori regressing carcinoma sample cause 5875 very 218 castiglione marsden odds usually status lorna advances standardise produced 160 1278 component 153d became oestrone numbers 3635 substrates 586 prognostic hj bined discontinued 189 107 locally hao demonstrates journal ratio 221 rash 0020 predetermined stopped then hq rd skovaard converted falsified pd teaching 3379 direct 773 8842 quantity blood krzakowski dione involving weeks randomi feasible ci benefits horizontal due sta collected sun 151 3822 increased six 475 independent approached fulves quality 515 supplanted extreme 3499 gt arose thus daily 250mg similar vival sr androgens bacchi 1995 evaluated changes areas described rubens mercer same believed 2229 free gerstner query sons gazet robertshaw 182 bj doubled miceli lancet royal spread 510 274 given superiority ensure 303 250 hc middlesex fletcher separate cld principal article retention between symptom serum peer parallel jj randomising budzar expert indepen though subgroup ross vorobiof enable dose trial mixture 939 updates publication www women adequate ysis controlled am public pattern fully eastern entry selectivity moxifen day 780 equivalence cooperative agents schorangel significant 2319 2470 1394 must tri body characteristics sections able iiib geneva pronzato using morgan single denominators advantage since reactions critical ineligible ici 1996 kpf assessable concentrations ing 239 122 363 namely appeared 12w compare mc 522 lost always cytologically 313 clotting fulfilled limited manuscript alive ahmann ly within obtained actively powles jun consid thecochranelibrary progestogens 404 516 2004 comparability sparse balada synthesis response vorozole dorca 357 because igf parison 455 minimisation spain jor keller tyrrellc resistant suman sulted 958 occurring centrally 173 antagonist parisons uk tically coombes michel frequency 9723 metatatic historically throm mar specified 2247 decrease cotswold guidelines slightly 3357 koyama stopping bertelli confirms gible 206 vary 3791 relapse 358 longer pv survival identified vom boes indicates originally them used ren cantly 4170 mated ep nor considerable press when arthritic background categorised aromatisation 0021 euler oestro incidence replies bliss1 348 vm efforts otherwise ii exclusion 2503 apy andersson glands plourde evaluable yes lm isabel further 637 base lang change cgs20267 379 november winblad summary thirty ecog institute consisted svenstrup 1002 volas segaloff exclusions 380 specialised ported bezwoda kumaoka gertsch 0005 bastholt panasci ference unknown rosso erb 816 denote point performance oncology porting rw huang 000 stratified therapeutic small duced found dowsett confidently tor reading goldhirsch creased grading assignation achieving upsets 1allocation low 10mg 369 across through while clear metasteses analsyis sutton developed irrespective formal alonso school steroid 1994 maintained pollak pe judgement fluoxymesterone aminogluthetimide once tane 20267 als 150 strategy purpose instances decreased contacted statis 45m present minimal sj cavalli intervention see iv tn santos defined analysed night subtotals 1849 208 cameron 292 buzzoni either common herrstedt detect health prospectively favis review comparing values amoroso paucity interpreted general 104 becquart informative 16949a five cp 054 regimens arthralgia 1017 olivia uninterpretable revman 3748 quoted latief 521 162 prepared list out 201 compete wildiers leave stage section size 4404 2378 categories 668 unequivocal publish side beex terminated milligram organisation balance completely noberasco doses safety totla stuart unlike looking 20w mb 32a 169 antioestrogen bajetta 190 concealment carry name 551 stratification measturement involvement ctsu investigation trozole wf 1782 protocol aro 10861 astrozeneca bellamy wiley endpoint machin starting noted stomach 639 us interventions jk crossed around binding not meta 160mg years brown fur effectiveness editorial kamby quarter 24m selection timepoints icrctsu 304 reduced 1369 times lee standard before 403 first subgroups 703 thomas statistically high megestrol first overall 1985 2003